Metagenomi Therapeutics, Inc. Common Stock (MGX) is a publicly traded Healthcare sector company. As of May 21, 2026, MGX trades at $1.30 with a market cap of $47.81M and a P/E ratio of -0.56. MGX moved +4.00% today. Year to date, MGX is -24.56%; over the trailing twelve months it is -24.12%. Its 52-week range spans $1.23 to $4.92. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces MGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for MGX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.30 |
| Market Cap | $47.81M |
| P/E Ratio | -0.56 |
| EPS | $-2.30 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.92 |
| 52-Week Low | $1.23 |
| Volume | 5.00K |
| Avg Volume | 0 |
| Revenue (TTM) | $22.33M |
| Net Income | $-85.89M |
| Gross Margin | 0.00% |
3 analysts cover MGX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.